OXN Oxonica

    RNS Number : 4672U
  Oxonica plc
  15 May 2008
   

    

    15 May 2008

    Oxonica plc

    Annual Report & Accounts and Notice of Annual General Meeting



    The Company's Annual Report and Financial Statements for the year to 31 December 2007 were posted to our shareholders on Thursday 15th
May together with Notice of the Annual General Meeting, which is to be held in the Oxford Room, Begbroke Science Park, Yarnton, Oxford, at
11am on Thursday 19th June.

    Copies are available for inspection free of charge at our registered office at 7 Begbroke Science Park, Sandy Lane, Yarnton, Kidlington,
Oxfordshire, OX5 1PF and from our website at www.oxonica.com.


    For further information, please contact:

    Oxonica plc                            01865 856 700
    Kevin Matthews, Chief Executive
    Richard Clarke, Finance Director

    The Broadcast PR Business    020 7812 6021
    Matthew Locke

    Panmure Gordon                    020 7459 3600
    Hugh Morgan
    Andrew Potts


    Notes to Editors

    About Oxonica plc - www.oxonica.com

    Oxonica (AIM: OXN.L) is one of the leading international nanomaterials groups with products already launched into international markets
and is listed in London on the AIM market. It was spun-out from Oxford University in 1999. Oxonica's mission is to focus on the development
of innovative commercial solutions for international markets using its expertise in the design and application of nanomaterials. It owns a
portfolio of demand driven products that offer substantial benefits to the target markets of energy, healthcare, materials and security.

    The Group currently has four operating divisions: Oxonica Energy, Oxonica Diagnostics, Oxonica Materials and Oxonica Security. Oxonica
has already launched products into international markets. Lead products include:
    *     Envirox* fuel combustion catalyst - a catalyst improving fuel economy and reducing emissions
    *     Optisol* UV absorber - a revolutionary photostable UV protection system designed to optimise the performance of quality sunscreens
and anti-premature aging products

    Oxonica is also active in searching for the next generation of products and is already engaged in developing transformational detection
technologies which will enable a new generation of ultrasensitive multiplex diagnostic tools for the clinical diagnostic life science and
security markets. In addition, Oxonica is developing other UV absorber technologies into polymer systems and coatings, based on similar
technologies to that used in Optisol*.
This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
ACSZGGMKKDGGRZM

Oxonica (LSE:OXN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Oxonica (LSE:OXN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024